The nummular phenotype of atopic dermatitis is clinically characterized by pruritic, coin‐
shaped plaques that are frequently recalcitrant to treatment. In this study, a retrospective …

The results from our dupilumab study in paediatric atopic dermatitis patients with nummular
eczema and prurigonodularis phenotypes are consistent with previous findings in adult …

Background Children with severe atopic dermatitis (AD) have a multidimensional disease
burden. Objective Here we assess the clinically meaningful improvements in AD signs …

Abstract Background/Objectives Psoriasiform eruptions after initiation of dupilumab have
been previously described in adults. This report details the risk of developing or unmasking …

Dupilumab is a relatively new and quite effective medication for recalcitrant atopic dermatitis
in patients over 6 years of age. Here, we present a 12‐year‐old girl with progressively …

Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD),
16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with …

The recent US Food and Drug Administration (FDA) approval of dupilumab for atopic
dermatitis (AD) has heralded “the decade of eczema,” but it may take several more years …

Introduction: Dupilumab has recently been shown to be effective in children under 6 years of
age with atopic dermatitis (AD). Nevertheless, real-life and long-term follow-up data are …

Background Pediatric patients with moderate-to-severe atopic dermatitis (AD) often
experience a high disease burden and have a high risk of persistent disease. Standard-of …

Abstract Background/Objectives Clinical trials of dupilumab have shown efficacy in treating
moderate‐to‐severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of …